Natera Inc. recently announced new findings from two clinical studies presented at the American Society of Hematology $(ASH)$ Annual Meeting. In a real-world analysis involving 144 patients with 14 subtypes of lymphoma, the Signatera test detected circulating tumor DNA (ctDNA) in 94% of pre-treatment samples. Results showed that ctDNA clearance during treatment was highly predictive of response to chimeric antigen receptor T-cell (CAR-T) therapy, and that rapid ctDNA clearance after one chemotherapy cycle correlated with better outcomes. Additionally, Signatera status at the end of first-line therapy was found to be highly prognostic for event-free survival, outperforming standard PET-CT assessments. In a separate HOVON study, conducted in collaboration with Foresight Diagnostics, the CLARITY ctDNA assay was used for longitudinal surveillance in 166 patients with diffuse large B-cell lymphoma. The study found that early molecular response, as detected by the assay, was associated with improved clinical outcomes. Following a negative ctDNA test, the probability of remaining relapse-free was 99% at six months and 97% at twelve months. Both studies underscore the potential of ctDNA assays for monitoring treatment response and long-term risk in lymphoma patients.